Cue Biopharma (NASDAQ:CUE) Trading Down 0.7% – Here’s What Happened

Cue Biopharma, Inc. (NASDAQ:CUE)’s stock price dropped 0.7% during trading on Monday . The stock traded as low as $29.44 and last traded at $30.95. Approximately 135,939 shares traded hands during trading, an increase of 9% from the average daily volume of 125,288 shares. The stock had previously closed at $31.16.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Wall Street Zen raised Cue Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Weiss Ratings upgraded Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Cue Biopharma Stock Performance

The company’s fifty day simple moving average is $27.31 and its two-hundred day simple moving average is $183.47. The stock has a market capitalization of $129.99 million, a PE ratio of -5.54 and a beta of 2.45.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.30) by $2.22. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%. The company had revenue of $5.69 million for the quarter, compared to the consensus estimate of $2.50 million.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Boothbay Fund Management LLC lifted its stake in Cue Biopharma by 15.3% in the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock valued at $215,000 after buying an additional 93,333 shares in the last quarter. Stifel Financial Corp increased its position in Cue Biopharma by 25.4% during the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after buying an additional 50,000 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc raised its holdings in shares of Cue Biopharma by 1,231.2% in the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after acquiring an additional 407,568 shares during the last quarter. GC Wealth Management RIA LLC raised its holdings in shares of Cue Biopharma by 35.0% in the fourth quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company’s stock worth $1,415,000 after acquiring an additional 1,200,000 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Cue Biopharma in the third quarter valued at $62,000. 35.04% of the stock is currently owned by institutional investors and hedge funds.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.